✦ LIBER ✦

81 Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)

✍ Scribed by B. Escudier; B.I. Rini; T.E. Hutson; M. Gore; S. Oudard; J. Tarazi; B. Rosbrook; J.A. Williams; S. Kim; R.J. Motzer

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

3006 POSTER DISCUSSION Time to Deteriora

✍ D. Cella; B. Escudier; B. Rini; C. Chen; H. Bhattacharyya; J. Tarazi; B. Rosbroo 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Axitinib versus sorafenib as second-line

✍ Motzer, Robert J; Escudier, Bernard; Tomczak, Piotr; Hutson, Thomas E; Michaelso 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 316 KB

Axitinib versus sorafenib as first-line

✍ Hutson, Thomas E; Lesovoy, Vladimir; Al-Shukri, Salman; Stus, Viktor P; Lipatov, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 317 KB

SUNITINIB AS FIRST-LINE TREATMENT FOR ME

✍ S. Oudard; R.J. Motzer; M.D. Michaelson; T.E. Hutson; P. Tomczak; R.M. Bukowski; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 74 KB

204 POSTER Recombinant IL-21 in combinat

✍ T.W. Flaig; B.D. Curti; M.S. Gordon; P.J. Van Veldhuizen; W.H. Miller; M.S. Erns 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 76 KB

7103 ORAL Association of Single Nucleoti

✍ Escudier, B.; Loomis, A.K.; Kaprin, A.; Motzer, R.; Tomczak, P.; Tarazi, J.; Kim 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB